Decatur Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Decatur Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-84,400	Closed	-$7.19M	–	58
2018 Q4	$7.19M	Buy	84,400 +15,800	+23%	+$1.5M	1.62%	26
2018 Q3	$6.65M	Sell	68,600 -17,050	-20%	-$1.7M	1.53%	33
2018 Q2	$8.07M	Buy	+85,650	New	+$7.5M	1.6%	33
2017 Q2	–	Sell	-77,345	Closed	-$6.79M	–	51
2017 Q1	$6.79M	Sell	77,345 -19,380	-20%	-$1.72M	1.32%	43
2016 Q4	$8.01M	Sell	96,725 -15,875	-14%	-$1.37M	1.15%	43
2016 Q3	$10.4M	Buy	+112,600	New	+$10.6M	1.31%	44

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Decatur Capital Management's BMRN Position: Q1 2019 in Review

Decatur Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 84,400 shares — an estimated $7.19M sold.

Decatur Capital Management first reported a position in BMRN in Q3 2016 and held it in 6 quarters. The position peaked at $10.4M in Q3 2016. 485 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

Decatur Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Decatur Capital Management sold 84,400 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $7.19M.
Decatur Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 6 quarters.
Decatur Capital Management's BioMarin Pharmaceuticals position peaked at $10.4M in Q3 2016.
485 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Decatur Capital Management's 13F filing for Q1 2019, filed 23 Apr 2019.